Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
芬兰科学院; 中国国家自然科学基金;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [1] Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients
    Xiaomin Zhang
    Jieli Yang
    Sai Chen
    Chang Liu
    Zhenhua Wang
    Hefei Ren
    Lin Zhou
    Journal of Thrombosis and Thrombolysis, 2022, 54 : 542 - 549
  • [2] The (Neutrophils plus Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen
    Pang, Yanbin
    Shao, Hong
    Yang, Ziheng
    Fan, Lixia
    Liu, Wenwen
    Shi, Jianhong
    Wang, Yuqing
    Han, Ying
    Yang, Lin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] Pre-existing diabetes mellitus in patients with multiple myeloma
    Chou, Yi-Sheng
    Yang, Ching-Fen
    Chen, Harn-Shen
    Yang, Sheng-Hsiang
    Yu, Yuan-Bin
    Hong, Ying-Chung
    Liu, Chun-Yu
    Gau, Jyh-Pyng
    Liu, Jin-Hwang
    Chen, Po-Min
    Chiou, Tzeon-Jye
    Tzeng, Cheng-Hwai
    Hsiao, Liang-Tsai
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (04) : 320 - 327
  • [4] Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej J.
    Kumar, Shaji
    Medhekar, Rohan
    Pei, Huiling
    Lefebvre, Patrick
    Kaila, Shuchita
    He, Jianming
    Lafeuille, Marie-Helene
    Cortoos, Annelore
    Londhe, Anil
    Mavros, Panagiotis
    Lin, Thomas S.
    Usmani, Saad Z.
    ONCOLOGIST, 2022, 27 (07) : E589 - E596
  • [5] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [6] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
    Sorrig, Rasmus
    Klausen, Tobias W.
    Salomo, Morten
    Vangsted, Annette J.
    Frolund, Ulf Christian
    Andersen, Kristian T.
    Klostergaard, Anja
    Helleberg, Carsten
    Pedersen, Robert S.
    Pedersen, Per T.
    Helm-Petersen, Sissel
    Teodorescu, Elena Manuela
    Preiss, Birgitte
    Abildgaard, Niels
    Gimsing, Peter
    PLOS ONE, 2017, 12 (12):
  • [7] Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma
    Chen, Dangui
    Zhan, Yang
    Yan, Hong
    Liang, Hong
    Yao, Fusheng
    Xu, Haitao
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (11) : 1017 - 1021
  • [8] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    Leukemia, 2011, 25 : 1620 - 1626
  • [9] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [10] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120